Study #2020-1313
A Randomized, Double-Blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination to Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339). Compared to Concurrent Chemoradiation Therapy Alone i
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Olaparib 300 mg BID, Pembrolizumab placebo (saline)
Description
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Small Cell Lung Cancer
Study phase:
Phase III
Physician name:
Carl Gay
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.